Vancomycin
- Generic Name
- Vancomycin
- Brand Names
- Firvanq, Vancocin
- Drug Type
- Small Molecule
- Chemical Formula
- C66H75Cl2N9O24
- CAS Number
- 1404-90-6
- Unique Ingredient Identifier
- 6Q205EH1VU
- Background
Antibacterial obtained from Streptomyces orientalis. It is a glycopeptide related to ristocetin that inhibits bacterial cell wall assembly and is toxic to kidneys and the inner ear.
As of January 29 2018, CutisPharma's Firvanq is the only FDA approved vancomycin oral liquid treatment option available for the the treatment of Clostridium difficile associated diarrhea and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains [LP1196]. Such an oral liquid formulation is expected to make Clostridium difficile associated diarrhea therapy more accessible in comparison to previously available specialty compounding products [LP1196].
- Indication
Administered intravenously, vancomycin is indicated in adult and pediatric patients for the treatment of septicemia, infective endocarditis, skin and skin structure infections, bone infections, and lower respiratory tract infections. Administered orally, vancomycin is indicated in adult and pediatric patients for the treatment of Clostridium difficile-associated diarrhea and for enterocolitis caused by Staphylococcus aureus (including methicillin-resistant strains).
- Associated Conditions
- Clostridium Difficile Associated Diarrhea (CDAD), Enterocolitis caused by Staphylococcus aureus, Infection caused by staphylococci, Severe Staphylococcal infection
Microbiome Effect of Omadacycline on Healthy Volunteers
- Conditions
- Healthy Volunteers
- Interventions
- First Posted Date
- 2023-09-08
- Last Posted Date
- 2025-03-25
- Lead Sponsor
- University of Houston
- Target Recruit Count
- 32
- Registration Number
- NCT06030219
- Locations
- 🇺🇸
University of Houston, Houston, Texas, United States
First Time Right of Vancomycin
- First Posted Date
- 2023-07-27
- Last Posted Date
- 2023-07-27
- Lead Sponsor
- Erasmus Medical Center
- Target Recruit Count
- 134
- Registration Number
- NCT05964114
Intra-wound Vancomycin Powder for Prevention of Surgical Site Infection Following Spinal Surgery
- First Posted Date
- 2023-07-25
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- Rabin Medical Center
- Target Recruit Count
- 363
- Registration Number
- NCT05959603
- Locations
- 🇮🇱
Rabin Medical Center, Petah tikva, Israel
Vancomycin in Primary Sclerosing Cholangitis in Italy
- Conditions
- Liver and Intrahepatic Bile Duct DisorderPrimary Sclerosing CholangitisIBD
- Interventions
- Other: Placebo
- First Posted Date
- 2023-05-25
- Last Posted Date
- 2023-07-03
- Lead Sponsor
- University of Milano Bicocca
- Target Recruit Count
- 84
- Registration Number
- NCT05876182
- Locations
- 🇮🇹
Fondazione IRCCS San Gerardo dei Tintori, Monza, Monza E Brianza, Italy
Vancomycin and Tobramycin Powder Use in Acute Open Fractures
- Conditions
- Infections
- Interventions
- Drug: Cephalosporin or clindamycin/vancomycin antibiotics..
- First Posted Date
- 2023-05-08
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- University of Utah
- Target Recruit Count
- 10
- Registration Number
- NCT05849090
- Locations
- 🇺🇸
University of Utah Orthopaedic Center, Salt Lake City, Utah, United States
Continuous vs. Intermittent Infusion Vancomycin
- Conditions
- Vancomycin
- Interventions
- First Posted Date
- 2023-04-21
- Last Posted Date
- 2025-01-06
- Lead Sponsor
- Aaron Cook
- Target Recruit Count
- 56
- Registration Number
- NCT05823116
- Locations
- 🇺🇸
University of Kentucky, Lexington, Kentucky, United States
Study of Aerosolized Antibiotics and Pembrolizumab in Advanced Non-small Cell Lung Cancer
- Conditions
- Advanced Non Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2023-03-21
- Last Posted Date
- 2025-04-22
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 20
- Registration Number
- NCT05777603
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Intramedullary Calcium Sulfate Antibiotic Depot
- Conditions
- Osteomyelitis TibiaOpen tíbia FractureTibial Fractures
- Interventions
- First Posted Date
- 2023-03-13
- Last Posted Date
- 2025-02-20
- Lead Sponsor
- Wake Forest University Health Sciences
- Target Recruit Count
- 497
- Registration Number
- NCT05766670
- Locations
- 🇺🇸
Atrium Health Cabarrus, Concord, North Carolina, United States
🇺🇸Pennsylvania State University, Hershey, Pennsylvania, United States
🇺🇸University of Kentucky, Lexington, Kentucky, United States
Lyophilized Fecal Microbiome Transfer vs. Vancomycin Monotherapy for Primary Clostridioides Difficile Infection
- Conditions
- Clostridioides Difficile Infection
- Interventions
- Combination Product: Lyophilized fecal microbiome transfer
- First Posted Date
- 2023-02-02
- Last Posted Date
- 2024-04-10
- Lead Sponsor
- Rambam Health Care Campus
- Target Recruit Count
- 196
- Registration Number
- NCT05709184
- Locations
- 🇭🇺
University of Debrecen, Debrecen, Hungary
🇮🇱Rambam Health Care Campus, Haifa, Israel
🇬🇧Imperial College of London, London, United Kingdom
LocalVancomycinPowderToPreventPeriprostheticJointInfection.
- Conditions
- Arthroplasty ComplicationsPeriprosthetic Fracture of Hip
- Interventions
- Procedure: Total knee or total hip arthroplasty
- First Posted Date
- 2023-01-26
- Last Posted Date
- 2023-02-10
- Lead Sponsor
- Assiut University
- Target Recruit Count
- 174
- Registration Number
- NCT05697965
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.